Definium Therapeutics, Inc. (DFTX)
NASDAQ:DFTX
Want to see DFTX full AI Analyst Report?
DFTX Stock Chart & Stats
$22.68
-$0.97(-11.96%)
At close: 4:00 PM EST
$22.68
-$0.97(-11.96%)
Day’s Range― - ―
52-Week Range$6.35 - $26.25
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.80M
Market Cap
$2.56B
Enterprise Value$2.30B
Total Cash (Recent Filing)$373.42M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.68
Next Earnings
Aug 06, 2026EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.50
Shares Outstanding109,066,780
10 Day Avg. Volume1,505,056
30 Day Avg. Volume1,797,289
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)3.60
Price to Sales (P/S)0.00
P/FCF Ratio-9.09
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-11.14
Forecast
1Y Price Target
$41.67Price Target Upside83.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.26
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Liquidity/runwayA $373.4M cash position materially reduces near-term financing risk and funds multiple Phase III readouts, NDA prep and commercialization buildout into 2028. This durable runway gives management time to reach clinical inflection points before needing dilutive financing.
Late-stage, Diversified Phase III ProgramA multi-study Phase III program across MDD, GAD and planned PTSD expansion creates multiple durable clinical catalysts and de-risks reliance on a single trial. Staggered endpoints and enrollment diversity improve the chance of at least one clear regulatory path and long-term franchise potential.
Low Leverage And Meaningful Equity BaseZero debt provides structural financial flexibility, avoiding interest obligations that could constrain R&D and commercialization spending. A material equity base, even if modestly declined, supports ongoing operations and strategic investments without immediate leverage pressure.
Bears Say
Pre-revenue With Widening LossesOperating without revenue and with accelerating net losses means capital is being consumed rather than compounded. Over the medium term this increases reliance on external funding, heightens dilution risk, and constrains optionality if clinical results or timelines slip.
Sustained Negative Operating Cash FlowConsistent negative operating and free cash flow requires recurring financing to sustain development. This structural cash burn limits runway sensitivity to trial timing and outcome, and pressures capital allocation decisions, potentially forcing dilution or reduced investment if milestones delay.
Commercial And Regulatory Execution RiskThe company's path to durable revenue depends on positive pivotal outcomes plus favorable FDA, coding and payer decisions. Even strong clinical data may face labeling, scheduling or reimbursement hurdles that could delay adoption, limit pricing power, or increase launch complexity.
Definium Therapeutics News
DFTX FAQ
What was Definium Therapeutics, Inc.’s price range in the past 12 months?
Definium Therapeutics, Inc. lowest stock price was $6.34 and its highest was $26.25 in the past 12 months.
What is Definium Therapeutics, Inc.’s market cap?
Definium Therapeutics, Inc.’s market cap is $2.56B.
When is Definium Therapeutics, Inc.’s upcoming earnings report date?
Definium Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 68 days.
How were Definium Therapeutics, Inc.’s earnings last quarter?
Definium Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$0.71 earnings per share for the quarter, missing the consensus estimate of -$0.492 by -$0.218.
Is Definium Therapeutics, Inc. overvalued?
According to Wall Street analysts Definium Therapeutics, Inc.’s price is currently Undervalued.
Does Definium Therapeutics, Inc. pay dividends?
Definium Therapeutics, Inc. does not currently pay dividends.
What is Definium Therapeutics, Inc.’s EPS estimate?
Definium Therapeutics, Inc.’s EPS estimate is -0.56.
How many shares outstanding does Definium Therapeutics, Inc. have?
Definium Therapeutics, Inc. has 109,066,780 shares outstanding.
What happened to Definium Therapeutics, Inc.’s price movement after its last earnings report?
Definium Therapeutics, Inc. reported an EPS of -$0.71 in its last earnings report, missing expectations of -$0.492. Following the earnings report the stock price went down -4.957%.
Which hedge fund is a major shareholder of Definium Therapeutics, Inc.?
Currently, no hedge funds are holding shares in DFTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Definium Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.67 (83.72% Upside)
$41.67 (83.72% Upside)
Blogger Sentiment
Bullish
DFTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
233.19%
12-Months-Change
Fundamentals
Return on Equity
-102.48%
Trailing 12-Months
Asset Growth
45.75%
Trailing 12-Months
Company Description
Definium Therapeutics, Inc.
Definium Therapeutics, Inc. is a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
DFTX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasizes strong clinical momentum (multiple Phase III programs with imminent topline readouts, Breakthrough Therapy designation in GAD, high statistical power in key studies), a clear commercialization plan and a solid cash position ($373.4M runway into 2028). These positives are tempered by materially higher operating expenses and a sizable YOY increase in net loss (driven by program investment and a non-cash warrant valuation change), design-related placebo risk from Phase II, and remaining regulatory and payer uncertainties that could affect timing and labeling. On balance, management’s message is forward-looking and execution-focused with meaningful near-term inflection points.View all DFTX earnings summariesDFTX Stock 12 Month Forecast
Average Price Target
$41.67
▲(83.72% Upside)
Technical Analysis
AnaptysBio
―
Enliven Therapeutics
―
Tyra Bioscience
―
Biohaven Ltd.
―
Inhibrx Biosciences Inc
―
Ownership Overview
1.58% Insiders
8.67% Mutual Funds
34.53% Other Institutional Investors
46.32% Public Companies and Individual Investors